WAUKEGAN, Ill.--(BUSINESS WIRE)--NEOPHARM, Inc. (Nasdaq: NEOL) today announced that it had been notified by the staff of the U.S. Securities and Exchange Commission, or SEC, that the SEC’s investigation, which commenced in March 2004 and which the Company believes concerned its disclosures regarding the development of its LED and LEP drug product candidates, has been terminated and no enforcement action recommended. The decision of the SEC to terminate its investigation is not a finding or judgment regarding the matters investigated.
